Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5)

The conclusion of the Expert Council reports an agreement on the place of the P2Y12 receptor blocker prasugrel in the early invasive treatment of patients with acute coronary syndrome ACS, according to the results of the multicenter randomized controlled study ISAR-REACT 5. Prasugrel should be consi...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: S. N. Tereshchenko, M. G. Glezer, S. A. Abugov, O. V. Averkov, S. I. Antipov, A. S. Galyavich, M. Yu. Gilyarov, D. V. Duplyakov, A. A. Efremushkina, D. A. Zateyshchikov, V. V. Ivanenko, E. D. Kosmacheva, O. V. Krestyaninov, Yu. M. Lopatin, E. P. Panchenko, V. V. Ryabov, E. V. Samokhvalov, I. I. Staroverov, S. A. Ustyugov, A. V. Khripun, S. V. Shalaev, R. M. Shakhnovich, I. S. Yavelov, A. N. Yakovlev, S. S. Yakushin
Format: Artigo
Langue:Russo
Publié: «FIRMA «SILICEA» LLC 2019-11-01
Collection:Российский кардиологический журнал
Sujets:
acute coronary syndrome
prasugrel
p2y12 receptor blocker
Accès en ligne:https://russjcardiol.elpub.ru/jour/article/view/3640
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires